Intravitreal bevacizumab in a patient with neovascular glaucoma.
The utility of intravitreal bevacizumab injection in a patient with neovascular glaucoma following central retinal vein occlusion is explored. Bevacizumab (1 mg in 0.04 mL) was used after failed intraocular pressure (IOP) control with transscleral cyclophotocoagulation and panretinal photocoagulation. IOP improved within 2 days and the patient experienced marked improvement in comfort. Bevacizumab may be an effective medication for the treatment of neovascular glaucoma.
Kahook
Malik Y
MY
UPMC Eye Center, Eye and Ear Institute, Pittsburgh, Pennsylvania 15213, USA.
Schuman
Joel S
JS
Noecker
Robert J
RJ
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D007498:Iris / Q000098:blood supply; D009389:Neovascularization, Pathologic / Q000150:complications; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab